- Raised $4.8M funding round, Feb 2014
About
Bioblast Pharma is a biotechnology company that develops therapies for patients with rare and ultra-rare genetic diseases. The company is building a diverse portfolio of product candidates with the potential to treat patients with incurable rare diseases. Cabaletta is a mutant protein-stabilizing platform based on a small repurposed molecule. Mutant unstable cellular proteins are the cause of several genetic diseases known as PolyA/Poly Q, including OPMD, SBMA, and SCA3. BBrm is a read-through platform based on a small repurposed molecule. The platform enables the read-through (or bypassing) of genetic defects, called nonsense mutations or stop codons, that interfere with normal protein formation. mPRT is a mitochondrial protein replacement platform based on biological fusion proteins. The platform is aimed at mitochondrial protein deficiency diseases and is capable of replacing missing or mutated proteins in mitochondria and restoring cell function. In March 2019, Enlivex Therapeutic which is developing a treatment for graft versus host disease, a deadly side effect of bone marrow transplants, has announced the completion of its merger into Nasdaq stock exchange shell Bioblast Pharma.
Funding history · 1 round · $39.8M total
Q&A
- What is Bioblast Pharma's primary focus?
- Bioblast Pharma is a biotechnology company that develops therapies for patients with rare and ultra-rare genetic diseases.
- What is the current operational status of Bioblast Pharma?
- Bioblast Pharma is currently inactive, having ceased operations in April 2019.
- Where is Bioblast Pharma headquartered?
- Bioblast Pharma's headquarters are located in Tel Aviv-Yafo, Israel.
- What was Bioblast Pharma's total funding raised?
- Bioblast Pharma raised a total of $39,750,000.
- When was Bioblast Pharma founded?
- Bioblast Pharma was founded in January 2012.
- How many employees did Bioblast Pharma have?
- Bioblast Pharma had 1-10 employees.
- What is the Cabaletta platform developed by Bioblast Pharma?
- Cabaletta is a mutant protein-stabilizing platform based on a small repurposed molecule, designed to treat genetic diseases caused by unstable cellular proteins like OPMD, SBMA, and SCA3.
- What is the BBrm platform developed by Bioblast Pharma?
- BBrm is a read-through platform based on a small repurposed molecule that enables the bypassing of genetic defects (nonsense mutations or stop codons) that interfere with normal protein formation.
- What happened to Bioblast Pharma in March 2019?
- In March 2019, Enlivex Therapeutic completed its merger into Bioblast Pharma, which became a Nasdaq stock exchange shell.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/8740289 | |
| YouTube | youtube.com/user/bioblastpharma |
Identifiers & details
| Founded | 2012-1 |
|---|---|
| Employees (exact) | 2 |
| Offices | New Haven |
| Status reason | Non Active, Apr 2019 ceased to operate |